(PRCT) Procept Biorobotics - Ratings and Ratios
Surgical Robot System,Aquablation Therapy
PRCT EPS (Earnings per Share)
PRCT Revenue
Description: PRCT Procept Biorobotics
PROCEPT BioRobotics Corporation is a surgical robotics company that focuses on developing innovative solutions for urology, both domestically and internationally. The companys flagship products, AquaBeam Robotic System and HYDROS Robotic System, provide image-guided robotic therapy for treating benign prostatic hyperplasia (BPH), a common condition affecting millions of men worldwide.
To evaluate the companys performance, we can examine key performance indicators (KPIs) such as revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. Given the companys negative P/E ratio and RoE, its likely that PROCEPT BioRobotics is still in the growth phase, investing heavily in R&D to expand its product offerings and market share. A closer look at the companys financials would reveal whether the revenue growth is accelerating and if the gross margin is improving, indicating a potential path to profitability.
From a market perspective, the demand for robotic-assisted surgeries is increasing due to the benefits of minimally invasive procedures, such as reduced recovery time and fewer complications. As a pioneer in the urology robotics space, PROCEPT BioRobotics is well-positioned to capitalize on this trend. To gauge the companys competitive advantage, we can analyze its market share, customer adoption rates, and the competitive landscape.
To further assess the companys prospects, we can examine metrics such as the number of procedures performed using their systems, the growth rate of their installed base, and the expansion of their sales and marketing efforts. By analyzing these KPIs, we can gain a deeper understanding of PROCEPT BioRobotics potential for long-term success and its attractiveness as an investment opportunity.
PRCT Stock Overview
| Market Cap in USD | 2,086m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-09-15 |
PRCT Stock Ratings
| Growth Rating | -26.4% |
| Fundamental | 33.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -61.6% |
| Analyst Rating | 4.40 of 5 |
PRCT Dividends
Currently no dividends paidPRCT Growth Ratios
| Growth Correlation 3m | -88.3% |
| Growth Correlation 12m | -86% |
| Growth Correlation 5y | 67.4% |
| CAGR 5y | -2.51% |
| CAGR/Max DD 3y | -0.04 |
| CAGR/Mean DD 3y | -0.13 |
| Sharpe Ratio 12m | -1.94 |
| Alpha | 0.02 |
| Beta | 0.530 |
| Volatility | 55.05% |
| Current Volume | 1067.8k |
| Average Volume 20d | 911.9k |
| Stop Loss | 34.9 (-6.4%) |
| Signal | -1.51 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-84.1m TTM) > 0 and > 6% of Revenue (6% = 16.5m TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA 15.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 148.5% (prev 158.0%; Δ -9.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.16 (>3.0%) and CFO -83.2m > Net Income -84.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (55.4m) change vs 12m ago 7.41% (target <= -2.0% for YES) |
| Gross Margin 64.19% (prev 53.27%; Δ 10.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.97% (prev 47.17%; Δ 14.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -21.58 (EBITDA TTM -81.0m / Interest Expense TTM 3.88m) >= 6 (WARN >= 3) |
Altman Z'' -4.67
| (A) 0.80 = (Total Current Assets 458.1m - Total Current Liabilities 49.7m) / Total Assets 513.1m |
| (B) -1.15 = Retained Earnings (Balance) -590.3m / Total Assets 513.1m |
| warn (B) unusual magnitude: -1.15 — check mapping/units |
| (C) -0.19 = EBIT TTM -83.8m / Avg Total Assets 443.7m |
| (D) -4.64 = Book Value of Equity -590.4m / Total Liabilities 127.3m |
| Total Rating: -4.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.17
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -5.63% = -2.82 |
| 3. FCF Margin -37.69% = -7.50 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -0.69 = -2.50 |
| 6. ROIC - WACC (= -28.40)% = -12.50 |
| 7. RoE -23.73% = -2.50 |
| 8. Rev. Trend 99.12% = 7.43 |
| 9. EPS Trend 81.32% = 4.07 |
What is the price of PRCT shares?
Over the past week, the price has changed by -1.58%, over one month by -6.58%, over three months by -36.26% and over the past year by -54.16%.
Is Procept Biorobotics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PRCT is around 28.38 USD . This means that PRCT is currently overvalued and has a potential downside of -23.87%.
Is PRCT a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PRCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 65.6 | 76% |
| Analysts Target Price | 65.6 | 76% |
| ValueRay Target Price | 31.4 | -15.7% |
Last update: 2025-09-12 04:43
PRCT Fundamental Data Overview
CCE Cash And Equivalents = 302.7m USD (Cash And Short Term Investments, last quarter)
P/S = 7.5881
P/B = 5.4079
Beta = 1.025
Revenue TTM = 274.9m USD
EBIT TTM = -83.8m USD
EBITDA TTM = -81.0m USD
Long Term Debt = 51.5m USD (from longTermDebt, last quarter)
Short Term Debt = 4.12m USD (from shortTermDebt, last quarter)
Debt = 55.6m USD (Calculated: Short Term 4.12m + Long Term 51.5m)
Net Debt = -223.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.84b USD (2.09b + Debt 55.6m - CCE 302.7m)
Interest Coverage Ratio = -21.58 (Ebit TTM -83.8m / Interest Expense TTM 3.88m)
FCF Yield = -5.63% (FCF TTM -103.6m / Enterprise Value 1.84b)
FCF Margin = -37.69% (FCF TTM -103.6m / Revenue TTM 274.9m)
Net Margin = -30.60% (Net Income TTM -84.1m / Revenue TTM 274.9m)
Gross Margin = 64.19% ((Revenue TTM 274.9m - Cost of Revenue TTM 98.5m) / Revenue TTM)
Tobins Q-Ratio = -3.12 (set to none) (Enterprise Value 1.84b / Book Value Of Equity -590.4m)
Interest Expense / Debt = 1.61% (Interest Expense 895.0k / Debt 55.6m)
Taxrate = 21.0% (US default)
NOPAT = -83.8m (EBIT -83.8m, no tax applied on loss)
Current Ratio = 9.21 (Total Current Assets 458.1m / Total Current Liabilities 49.7m)
Debt / Equity = 0.14 (Debt 55.6m / last Quarter total Stockholder Equity 385.8m)
Debt / EBITDA = -0.69 (Net Debt -223.3m / EBITDA -81.0m)
Debt / FCF = -0.54 (Debt 55.6m / FCF TTM -103.6m)
Total Stockholder Equity = 354.6m (last 4 quarters mean)
RoA = -16.40% (Net Income -84.1m, Total Assets 513.1m )
RoE = -23.73% (Net Income TTM -84.1m / Total Stockholder Equity 354.6m)
RoCE = -20.63% (Ebit -83.8m / (Equity 354.6m + L.T.Debt 51.5m))
RoIC = -20.60% (NOPAT -83.8m / Invested Capital 406.6m)
WACC = 7.80% (E(2.09b)/V(2.14b) * Re(7.97%)) + (D(55.6m)/V(2.14b) * Rd(1.61%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.99%
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -103.6m)
EPS Correlation: 81.32 | EPS CAGR: 27.15% | SUE: 1.12 | # QB: 1
Revenue Correlation: 99.12 | Revenue CAGR: 63.90% | SUE: 1.65 | # QB: 2
Additional Sources for PRCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle